Navigation Links
Cerecor Announces Clearance of IND for FP01
Date:4/11/2012

BALTIMORE, April 11, 2012 /PRNewswire/ -- Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, today announced that its Investigational New Drug (IND) Application for FP01 for the treatment of cough has cleared the 30 day deliberation period by the U.S. Food and Drug Administration (FDA).  The Company plans to immediately characterize the pharmacokinetics of FP01 lozenges in humans and thereafter to initiate an exploratory Phase II acute cough study in healthy subjects with upper respiratory tract infections (URTI). 

(Logo: http://photos.prnewswire.com/prnh/20120411/PH85852LOGO )

"Acceptance by the FDA of this application and the advancement of FP01 to clinical testing are important milestones for the Company and key steps along the path to commercialize a treatment for acute and chronic cough. The data we plan to generate from the initial Phase II study will educate us about the effect size of FP01 as an antitussive, providing for future studies," said Dr. Blake Paterson, CEO and co-founder of Cerecor.

About Cerecor Inc.

Cerecor Inc. ("Cerecor" or the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. Cerecor is focused on translational medicine -- the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. Cerecor's product pipeline also includes preclinical drug development candidates in cognition and schizophreniawww.cerecor.com

For More Information, contact:
John Dierkes
Kennedy Advisors
john@kennedyadvice.com
(410) 935-9334


'/>"/>
SOURCE Cerecor Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Botanic Announces Results of Annual General Meeting
2. iBio Announces Production of Biosimilar Palivizumab with its iBioLaunch™ Technology
3. SafeWire, LLC. Announces first US product launch of Y-wire™
4. Sunpeaks Ventures Announces Letter of Intent to Export Clotamin to Top Russian Pharmacies
5. Rapid Fire Marketing Announces the First Shipment of its Vapor Inhaler Model Named the CannaCig Has Passed All Patient Tests; Second Round of Production to Start This Week
6. Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores
7. Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2012 Results
8. BioNeutral Group Announces Positive Results for the Ygiene 206 Sterilization Tests
9. Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
10. BONESUPPORTS New CEO Announces 100 Day Plan
11. Sunpeaks Ventures Announces Agreement with Albeck Financial Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ISELIN, New Jersey , April 29, 2016 ... Omnichannel Software Suite for Life Sciences, Product Development ... and Global Life Science Customer Base . ... healthcare solutions provider, today announced the acquisition of ... is a global leader in adaptive sales enablement ...
(Date:4/29/2016)... Automation is one of the ... the growing demands for productivity in speed, accuracy, throughput ... are already adept of a wide range of functions ... labor. Instrumentation continues to evolve, and is poised to ... few years ago. Originally used mostly by the big ...
(Date:4/28/2016)... -- Research and Markets has announced the ... 2016-2020" report to their offering.      ... global plastic surgery products market is expected to grow ... , ,The growing adoption of laser in aesthetics is ... market. Lasers are used to treat a broad range ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... infants born with severe congenital diaphragmatic hernia have better survival rates if surgery ... diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Mobility Designed ... put pressure on the armpits, the M+D Crutch evenly distributes body weight from the ... wrists and hands when using the crutches than with other crutches. , Co-founders Max ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston ... and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its ... is a newly patented safety device secured by nasal surgeons onto the floor ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... feature Grassland Dairy Products, Inc. in an upcoming episode, airing third quarter 2016 ... century of churning cream into butter, Grassland Dairy Products, located in Greenwood, Wisconsin ...
Breaking Medicine News(10 mins):